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Abstract
Although it is known that two-tier serologic testing for Lyme disease may be associated with false positive results on the IgM immuno-
blot, this problem has never been systematically studied in the clinical practice setting. In a retrospective investigation of patients
referred to the private adult practice of an Infectious Diseases physician for possible for Lyme disease, 50 of 182 patients (27.5%, 95%
CI: 21.1–34.6) were found to have a false positive IgM immunoblot. 78.0% of these patients had received unnecessary antibiotic therapy.
False positive results were not restricted to any single commercial laboratory. Research on alternative testing strategies that eliminate
the IgM immunoblot entirely is warranted.
Keywords: Borrelia burgdorferi, diagnosis, IgM immunoblot, Lyme disease, serology
Original Submission: 16 September 2011; Revised Submission: 15 November 2011; Accepted: 30 November 2011
Editor: D. Raoult
Article published online: 9 December 2011
Clin Microbiol Infect 2012; 18: 1236–1240
10.1111/j.1469-0691.2011.03749.x
Corresponding author: G. P. Wormser, New York Medical Col-
lege, Division of Infectious Diseases, Munger Pavilion, Room 245,
Valhalla, NY 10595, USA
E-mail: gary_wormser@nymc.edu
Introduction
Lyme disease caused by Borrelia burgdorferi is the most com-
monly reported vector-borne infection in North America
[1]. Clinical manifestations may involve the skin and result in
a characteristic skin lesion, erythema migrans. Extracutane-
ous manifestations may involve the nervous system, heart or
musculoskeletal system [2]. Although in endemic areas ery-
thema migrans is distinctive enough to permit an accurate
diagnosis based on physical examination, none of the other
manifestations of Lyme disease can reliably be diagnosed
based solely on clinical findings [2]. Tests for antibody to
B. burgdorferi have been the mainstay of laboratory diagnosis
for patients with such manifestations [3].
The sensitivity of serologic testing has generally been ade-
quate in patients with extracutaneous manifestations of Lyme
disease. However, lower than desired specificity has been a
long-standing problem. Lack of specificity prompted the
introduction of a two-tier testing strategy in 1995 [4].
According to those guidelines from the Centers for Disease
Control and Prevention (CDC), which remain in current
usage, seropositivity requires a reactive first-tier test, usually
an enzyme-linked immunosorbent assay (ELISA), plus either a
positive IgM or a positive IgG immunoblot. If a patient’s
symptoms have exceeded 4 weeks, the IgG immunoblot in
particular must be positive. Immunoblots are not considered
positive unless the reactive bands present are those that sat-
isfy the recommended evidence-based criteria for positivity.
Although the specificity of two-tier serologic testing has
exceeded 99% in research studies when the testing was per-
formed by highly proficient reference laboratories [5], in
actual clinical practice two-tier testing has performed less
well, presumably due to over-reading of weak bands on the
IgM immunoblot [5–7]. Despite recognition of this problem
by many health care providers in clinical practice, it has
never been systematically studied in this setting. Because
false positive Lyme IgM immunoblots may lead to misdiagno-
sis, unnecessary antibiotic therapy with possible adverse
effects, and thereby unnecessary expenditures, we attempted
to examine this phenomenon in the clinical practice of one
of the coauthors of this report (GPW).
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Methods
The office of research administration at New York Medical
College approved this retrospective study, in which the med-
ical records of all patients seen in the adult Infectious Dis-
eases private practice of one of us (GPW) from September
2007 through June 2010 were reviewed. This time period
was chosen in order to arrive at an estimated sample size of
at least 150 patients who were evaluated because of possible
Lyme disease. Patients referred for reasons other than possi-
ble Lyme disease were excluded.
Criteria used to Evaluate the IgM
Immunoblot
Four criteria (Table 1) were used to evaluate whether the
IgM immunoblot was likely to be false-positive: 1. whether
the CDC criteria for seropositivity were satisfied [4]; 2.
whether there was likely to have been tick exposure; 3.
whether the patient’s symptoms and signs were suggestive of
those found in early Lyme disease [2,8]; and 4. whether the
finding of seropositivity was reproducible on retesting within
a 4 week time period. Although tick exposure leading to the
development of early Lyme disease is theoretically possible
in colder months, we assumed that positive IgM immunoblot
test results occurring during the winter were most likely to
be false positive based on our clinical experience. In over
20 years we have not encountered a patient in our geo-
graphic area who developed an erythema migrans skin lesion
during the months of December through March. Lack of
reproducible seropositivity within 4 weeks of the initial test-
ing that showed a positive IgM immunoblot was included,
because persistence, and usually expansion, of the humoral
immune response is expected within this time frame even if
antibiotic treatment is prescribed [9,10].
Statistical Analysis
Categorical variables were compared by the Fisher’s exact
test (two-tailed), and continuous variables by the two-sample
t-test. Analyses were done using StataCorp’s statistical pack-
age Stata.
Results
A total of 249 patients were seen over the 34 month study
period, of which the medical records of 248 patients were
available for review. 182 patients (73.4%) were referred for
evaluation of possible Lyme disease. 94 patients had a positive
IgM immunoblot for antibodies to B. burgdorferi, of whom 50
(53.2%) were deemed to be false positive based on one or
more of the four criteria listed in Table 1. Indeed, all of the
patients fulfilled at least two of the criteria listed, 58% fulfilled
at least three and 16% fulfilled all four. Thus, 50 (27.5%, 95%
CI: 21.1–34.6) of the 182 referrals for possible Lyme disease
were found to have a false positive IgM immunoblot. None of
these 50 patients had a positive IgG immunoblot.
One of the 50 patients had no symptoms. Of the 49
symptomatic patients (Table 2) only one had an objective
TABLE 1. Criteria used to evaluate whether the IgM
immunoblot was likely to be false-positive
1 Failure to meet CDC criteria for seropositivity – 94%a
A First-tier test omitted – 40%a
B First-tier test negative – 22%a
C Symptoms in excess of 4 weeks with a negative IgG immunoblot – 90%a
D Immunoblot did not meet CDC band criteria for reactivity – 12%a
2. Lack of tick exposure – 42%a
A. Testing done in winter months of December, January, February or
March – 38%a
B. No exposure to geographic area where the vector ticks are known to be
present – 10%a
3. Symptoms atypical for early localized or early disseminated Lyme disease, i.e.,
no erythema migrans-like skin lesion, no acute febrile illness, no meningitis,
no cranial nerve palsy, no radiculopathy, and no evidence for myocarditis;
or asymptomatic – 98%a
4. Lack of seropositivity by repeat serologic testing within 4 weeks of the positive
IgM immunoblot – 40%a
CDC, Centers for Disease Control and Prevention.
aIndicates percentage of the 50 patients regarded as having a false positive IgM
immunoblot for antibodies to B. burgdorferi who fulfilled this criterion. Of the
four categories of criteria listed, all patients fulfilled at least two of them, 58%
fulfilled at least three, and 16% fulfilled all four.
TABLE 2. Symptoms present in the 49 symptomatic
patients with a false positive IgM
Arthralgia 29 (59.2%)
Fatigue 27 (55.1%)
Headache 25 (51.0%)
Myalgia 23 (46.9%)
Decreased Concentration 12 (24.5%)
Paresthesias 12 (24.5%)
Back pain 10 (20.4%)
Dizziness 8 (16.3%)
Feeling anxious 7 (14.3%)
Chills 7 (14.3%)
Rhinorrhea 7 (14.3%)
Feeling depressed 6 (12.2%)
Sleep disturbance 5 (10.2%)
Weight loss 5 (10.2%)
Chest pain 5 (10.2%)
Diarrhea/loose stool 5 (10.2%)
Sore throat 4 (8.2%)
Palpitation 4 (8.2%)
Photosensitivity 4 (8.2%)
Change in vision 4 (8.2%)
Change in hearing 3 (6.1%)
Imbalance 3 (6.1%)
Coughing 3 (6.1%)
Nausea/vomiting 2 (4.1%)
Hair loss 2 (4.1%)
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clinical manifestation suggestive of early localized or dissemi-
nated Lyme disease (a skin lesion), but this patient had been
ill for more than 8 weeks at the time of the serologic testing,
had a negative first-tier test at that time and had negative
repeat serologic testing within 4 weeks of the initial test.
Few patients had objective abnormalities, although one
patient had amyotrophic lateral sclerosis and at least four
other patients had various forms of arthritis unrelated to
B. burgdorferi infection.
Of the 50 patients found to have a false positive IgM
immunoblot, 47 of the 50 (94.0%) failed to meet CDC crite-
ria for seropositivity: 45 patients (90.0%) had symptoms in
excess of 4 weeks at time of testing, 39 (86.7%) of whom
had symptoms in excess of 8 weeks; 11 (22.0%) had a nega-
tive first-tier serologic test; 20 (40.0%) did not have a first
tier test done; and for 6 (12.0%) the bands required to meet
CDC criteria for a positive IgM immunoblot were not pres-
ent despite an interpretation of seropositivity by the labora-
tory performing the testing. Overall, 32 patients (64.0%) had
negative or no concomitant first-tier testing and/or the band
pattern did not meet CDC criteria.
Of the 19 patients with a reactive first-tier ELISA, the
index value was generally low; 13 (72.2%) of the 18 index
values that were available were less than twice the cut-off
for positivity, including 5 (27.8%) which did not reach the
cut-off and were in the equivocal range. 20 (90.9%) of 22
patients who were retested within 4 weeks of the positive
IgM immunoblot were seronegative.
Remarkably, 21 of the 50 patients (42.0%) were regarded
as having essentially no tick exposure because 19 were
tested during the winter months and five had no exposure
to tick infested areas (three were tested in the winter and
also had no geographic exposure).
False positive IgM immunoblots were not restricted to any
one particular commercial laboratory. However, two com-
mercial laboratories widely used in the Northeastern United
States accounted for 50% of the false positive results,
although only what have been referred to ‘Lyme speciality
laboratories’ [11] used interpretative criteria different from
what has been recommended by the CDC.
Patients with a false positive IgM immunoblot were signifi-
cantly more likely to be female (39/50 [78.0%] vs. 71/132
[53.8%], p 0.004). Females with a false positive IgM immuno-
blot were significantly younger than other females (females
with a false positive IgM, n = 39, mean age 46.5 years ± 13.7
vs. other females, n = 71, mean age 54.5 ± 15.9, p 0.009),
whereas males were not (males with a false positive IgM,
n = 11, mean age 47.7 years ± 12.2 vs. other males, n = 61,
mean age 51.2 ± 19.9, p 0.58). Overall, of the 94 patients
referred for possible Lyme disease by another physician, 23
(24.5%) had a false positive IgM immunoblot compared with
27 (30.7%) of the 88 self-referred patients, p 0.41.
At least 39 (78.0%) of the 50 patients with a false positive
IgM immunoblot had received antibiotic therapy because of this
finding. Indeed, 14 (28%) had received multiple courses of anti-
biotic therapy. One patient had received 6 months of antibiotic
therapy and 4 (10.3%) of the 39 patients who were treated had
even received a course of intravenous antibiotic treatment.
Discussion
The results of this retrospective investigation demonstrate
that false positive IgM immunoblot results are a relatively
common occurrence. Among the patients evaluated for possi-
ble Lyme disease in the private adult practice of an Infectious
Diseases physician, 50 out of 182 referrals were regarded as
having a false positive IgM immunoblot [27.5%, 95% CI: 21.1–
34.6]). False positive IgM immunoblot results were just as fre-
quent among patients referred by another physician as they
were among patients who were self-referred. False positive
results were not restricted to any single laboratory and were
most often generated by widely used commercial laborato-
ries. The IgM results led to one or more unnecessary courses
of antibiotic therapy in 78.0% of the patients, including intra-
venous antibiotic therapy in 10.3% of the antibiotic-treated
patients. False positive results were found disproportionately
among younger female patients; although this result is difficult
to explain, it may imply that serologic testing for Lyme disease
is more commonly requested for this group.
There are several limitations to this study. For example,
the results do not provide any information on the actual
specificity of the IgM immunoblots when performed by com-
mercial laboratories, only that such findings are commonly
encountered among patients referred for possible Lyme dis-
ease to a private practice of an Infectious Diseases physician
in a Lyme disease-endemic area. In addition, the practice of
this particular Infectious Diseases physician, who has had a
special interest in Lyme disease, may not be representative
of other Infectious Diseases practitioners in Lyme disease-
endemic areas or in non-endemic areas, or for those who
care for pediatric patients. However, anecdotal discussions
with other adult and pediatric Infectious Diseases practitio-
ners suggests that they are also routinely evaluating patients
suspected to have a false positive IgM immunoblot for anti-
bodies to B. burgdorferi.
In addition, it is possible that some of the IgM immunoblot
results were misclassified as false positive. The most conclusive
evidence for a false positive IgM immunoblot would require
that the exact same serum sample found to have a positive IgM
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immunoblot be retested and determined to be negative by an
experienced reference laboratory. Obviously, this could not
be accomplished in a retrospective study. However, objective
and reasonable criteria were used to classify the serologic
results in this study as likely to be false positive. Indeed, it is
probably more likely that some of the 44 positive IgM immuno-
blots that were regarded as true positives may have been mis-
classified. In any case, it is quite clear that some clinicians are
not following the CDC recommendations in place since 1995
for ordering conditional Lyme disease serologic testing [4], in
so far as immunoblot testing is being requested independently
of whether a first-tier test is reactive or even done. It is also
clear that some clinicians are either not aware of, or not fol-
lowing, the recommendations for interpretation of serologic
test results, because patients with chronic non-specific symp-
toms are being diagnosed and treated for Lyme disease based
solely on a positive IgM immunoblot test result.
The false positive IgM immunoblot results observed in this
study were probably related to over-reading of weak bands
for the most part (Figure 1), as has been suggested by others
[5–7]. Other infectious agents known to cause polyclonal B
cell stimulation resulting in false positive IgM immunoblots
for Lyme disease, such as Epstein-Barr virus [12], were not
diagnosed for this patient cohort. To improve the accuracy
of serologic testing for Lyme disease it has been recom-
mended that testing be limited to those with at least a
20% pretest probability of Lyme disease [13] and for IgM
immunoblot testing, in particular, restricting the testing to
patients with symptoms and signs of recent onset [4].
Research on alternative testing strategies that eliminate the
IgM immunoblot entirely is ongoing [5,6]. One approach that
has shown promise is the substitution of the C6 ELISA sero-
logic test for the immunoblots as the second-tier test. The
C6 ELISA is a commercially available assay that is highly sen-
sitive for early Lyme disease [14] and yet is usually indicative
of the presence of IgG rather than IgM antibodies to B. burg-
dorferi [15]. Additional research on this topic is warranted.
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the strip: 23 kDa, 39 kDa, or 41 kDa (arrows). Strip 1 was incubated with a positive control serum and displays sufficient reactivity at 23 and
41 kDa to be considered positive; there was only weak reactivity at 39 kDa. Strip 2 was incubated with the cutoff control serum and displays
reactivity at 23 kDa only (arrowhead). Strip 3 was incubated with a negative control serum and has no visible bands. Strip 24 was incubated with
a patient’s serum and displays several bands. However, all of the bands are of weaker intensity than the cutoff control band, and thus should not
be scored as present. Furthermore, only one of the bands (23 kDa) is at an appropriate location to be relevant according to the CDC recom-
mended IgM immunoblot criteria. Although there are weak bands in the general vicinity of 39 kDa and 41 kDa, they do not line up correctly.
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